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Immune predictors of oral poliovirus vaccine immunogenicity
among infants in South India
Sudhir Babji 1, Punithavathy Manickavasagam1, Yin-Huai Chen2, Nithya Jeyavelu1, Nisha Vincy Jose 1, Ira Praharaj 1,
Chanduni Syed1, Saravanakumar Puthupalayam Kaliappan 3, Jacob John3, Sidhartha Giri 1, Srinivasan Venugopal1,
Beate Kampmann4, Edward P. K. Parker4, Miren Iturriza-Gómara5, Gagandeep Kang1, Nicholas C. Grassly 6,7✉ and Holm H. Uhlig2,7
Identification of the causes of poor oral vaccine immunogenicity in low-income countries might lead to more effective vaccines. We
measured mucosal and systemic immune parameters at the time of vaccination with oral poliovirus vaccine (OPV) in 292 Indian
infants aged 6–11 months, including plasma cytokines, leukocyte counts, fecal biomarkers of environmental enteropathy and
peripheral blood T-cell phenotype, focused on gut-homing regulatory CD4+ populations. We did not find a distinct immune
phenotype associated with OPV immunogenicity, although viral pathogens were more prevalent in stool at the time of
immunization among infants who failed to seroconvert (63.9% vs. 45.6%, p= 0.002). Using a machine-learning approach, we could
predict seroconversion a priori using immune parameters and infection status with a median 58% accuracy (cross-validation IQR:
50–69%) compared with 50% expected by chance. Better identification of immune predictors of OPV immunogenicity is likely to
require sampling of mucosal tissue and improved oral poliovirus infection models.
npj Vaccines            (2020) 5:27 ; https://doi.org/10.1038/s41541-020-0178-5
BACKGROUND
The composition of the intestinal microbiota develops over the
first few years of life, and is shaped by multiple factors such as
mode of birth, breast-feeding, food intake and antibiotic use1,2. It
is regulated by infant immunity, which in turn develops and is
shaped by exposure to the microbiota3,4. Intestinal lymphoid
tissues require the intestinal microbiota for normal development,
and exposure to commensal and pathogenic organisms sets the
tone of the systemic and mucosal immune system for the long
term. These early interactions have a substantial impact on the
development of metabolic and immune-mediated disorders5.
There is also emerging evidence in mice and humans for
microbiota dependent modeling of local immunity and the
subsequent response to infection or vaccination6–8. Understand-
ing the complex interaction between the microbiota and immune
responses during infancy therefore has potentially important
implications for vaccine development as well as prevention of
immune-mediated disorders.
Infants in low and lower-middle income countries (LMICs) are
exposed to a high burden of intestinal pathogens from birth9,10. It
is thought that these infections alter intestinal immune system
homeostasis and eventually lead to environmental enteropathy
(EE). This understudied disorder is commonly found in children in
the poorest socioeconomic settings and is characterized by
intestinal inflammation, permeability and histological changes
including blunted intestinal villi11. Recent work has begun to
elucidate its contribution to malnutrition and changes in the
microbiota that may adversely affect nutrient uptake and
growth12–14.
It has also been suggested that EE may cause poor oral vaccine
immunogenicity15,16. Oral vaccines against poliovirus, rotavirus,
and cholera are all substantially less immunogenic and effective
when given to children in LMICs17. This phenomenon has
prolonged polio eradication by limiting vaccine effectiveness18,
and is limiting the benefits from the global scale-up in access to
oral rotavirus vaccines19. However, recent studies of biomarkers of
EE in children at the time of immunization have had mixed
findings, with different biomarkers showing positive, negative or
no association with oral poliovirus or rotavirus vaccine immuno-
genicity20. Several other mechanisms may also contribute to poor
oral vaccine immunogenicity in LMICs, including interference by
high titers of antigen-specific transplacental or breastmilk
antibodies. However, withholding breastfeeding does not improve
oral poliovirus or rotavirus vaccine response21–24, and neonatal
immunization when transplacental antibody titres are at their
highest has in general resulted in comparable levels of
seroconversion to doses administered later in life25,26.
In the case of oral poliovirus vaccine (OPV), enterovirus infection
at the time of vaccination is associated with a modest decline in
vaccine immunogenicity27,28. Recent data suggest this may be the
case for oral rotavirus vaccine too29, which is also affected by co-
administration of the live-attenuated OPV30. The mechanisms
underlying this association are unclear and may relate to direct
interference at mucosal and epithelial sites affecting virus
replication and modulation of innate and adaptive immunity.
Here we report an investigation of the mechanisms behind poor
OPV immunogenicity and the contribution of changes in systemic
and mucosal immune homeostasis, including EE. We measured
systemic and mucosal immune parameters in peripheral blood
and stool samples collected at the time of monovalent serotype 3
OPV immunization of seronegative Indian infants aged
6–11 months. These infants were enrolled in a randomized
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controlled trial of the effect of the antibiotic azithromycin on EE
and OPV immunogenicity31. As primary outcome, we reported
that azithromycin treatment had no effect on seroconversion after
OPV, despite reducing the enteric bacterial pathogen load and
fecal biomarkers of EE. Instead, infection with enteric viruses
(enteroviruses and rotavirus) was associated with seroconversion.
We now report on extensive immune profiling of these infants at
the time of immunization, including mucosal homing immune
cells in peripheral blood, plasma cytokines and acute-phase
proteins, leukocyte counts, and fecal biomarkers of inflammation.
We use a statistical learning approach to identify immune markers
measured at the time of vaccination that predict OPV immuno-
genicity. We end with a consideration of the implications of our
findings for improving oral vaccines and oral vaccination
strategies.
RESULTS
Study population
We measured markers of innate and adaptive, mucosal and
systemic immunity in Indian infants aged 6–11 months and who
lacked detectable antibodies at 1:8 dilution to serotype 3
poliovirus at the time of immunization with monovalent type 3
OPV (mOPV3) as part of a clinical trial of the effect of azithromycin
on the immunogenicity of this vaccine. In the original study, 50%
of infants given azithromycin seroconverted after vaccination with
mOPV3, compared with 54% given placebo. Out of the 300 infants
randomly selected for this study (stratified by study arm and
seroconversion status), 292 completed the study per protocol and
were included in our analysis of immune markers. Ex vivo flow
cytometry was performed in 129 infants to examine circulating
gut-homing T-cell phenotypes (Fig. 1).
Immune measurements
Total cell counts were measured from freshly collected blood
samples. We separated peripheral blood mononuclear cells
(PBMCs) and plasma within 4–6 h of collection and measured
lymphocyte gut-homing markers, plasma cytokines and acute
phase proteins (see Methods section for full details). Data on
seroconversion to mOPV3, vaccine virus shedding 7 days after
immunization, stool inflammatory biomarkers and pathogens
detected by Taqman array card (TAC) were also analyzed as
previously reported31.
A cross-correlation matrix among all investigated markers shows
strong associations among parameters within each class of measure-
ments (measurement ‘module’) but weaker associations across
modules (Fig. 2a). Unsupervised clustering of immune parameters
did not reveal any strong association of immune phenotype with
seroconversion to mOPV3 or treatment arm (Fig. 2b).
Demographic and seasonal correlates of immune phenotype
Fecal calprotectin and other biomarkers of EE, C-reactive protein
(CRP) as a measure of systemic inflammation, plasma cytokines
and leukocyte populations, did not differ significantly by age-
group or sex after false discovery rate (FDR) correction of p-values
(Table 1). There were, however, significant differences in
measurements according to the time of year the sample was
collected, suggesting an important seasonal component. Mea-
sures of intestinal inflammation, including calprotectin, were
raised among infants immunized in September–October com-
pared with November–December (Table 1). In contrast, markers of
systemic inflammation including interferon-γ (IFN-γ) and inter-
leukin-1β (IL-1β) in plasma and neutrophil counts, were higher
during November–December. Nearly all infants (271/292) were
breastfed and breastfeeding status was not associated with
immune phenotype (p > 0.8 for all variables in Table 1).
Effect of intestinal infection with pathogenic viruses and bacteria
The number of bacterial or viral pathogens detected in stool at the
time of vaccination did not show any significant correlation with
EE biomarkers, plasma cytokines, CRP or lymphocyte populations
after FDR correction of p-values (Table 1). Calprotectin was raised
in infants with bacterial pathogens detected in stool, in agreement
with expectations from previous work, but this was not significant
after FDR correction31. Viral pathogens were more prevalent
among those infants who failed to seroconvert to OPV (prevalence
of at least one viral pathogen was 63.9% vs. 45.6%, Fisher’s p=
0.002), as previously reported31. However, detection of any
pathogenic virus in stool was not correlated with any of the
immune parameters after FDR correction.
754 seronegative infants
randomised to
azithromycin or placebo
348 complete
study per-protocol
357 complete
study per-protocol
Immunology subset
144 (target 150)
Immunology subset
148 (target 150)
ex vivo FACS
64 infants
ex vivo FACS
65 infants
EE biomarkers (days 0 &14 stool, day 14 plasma)
cytokines, growth factors, CRP (day 14 plasma)
leukocyte counts (day 14 fresh PBMC)
OPV shedding (day 21 stool)
flow cytometry (day 14 fresh PBMC)
OPV seroconversion (day 35 serum)
Intestinal pathogens (days 0 &14 stool)
8454 infants aged 
6-11 mths screened for
P3 antibodies
367 received
mOPV3
367 received
mOPV3
376 received 
azithromycin
378 received
placebo
Day 0
Day 14
Day 35
Fig. 1 Flow chart of infants included in the analysis. P3 poliovirus serotype 3, mOPV3 monovalent serotype 3 oral poliovirus vaccine, PBMC
peripheral blood mononuclear cells, EE environmental enteropathy, CRP C-reactive protein.
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Effect of treatment with azithromycin
As reported in Grassly et al.31, treatment with azithromycin
reduced fecal biomarkers of EE (myeloperoxidase, calprotectin,
and α1-antitrypsin) and the prevalence of pathogenic Escherichia
coli and Campylobacter bacteria detected in stool, but did not
affect seroconversion to OPV which was 50% and 54% in the
treatment and placebo arms respectively. Here we report that
azithromycin, despite significantly reducing fecal calprotectin
level, did not affect measures of systemic inflammation such as
CRP (0.88 mg/L among infants in the treatment arm at the time of
vaccination compared with 0.94 mg/L in the placebo arm) or other
immune parameters of interest, including circulating CD4+ T cells
expressing intestinal or mucosal homing markers and the
regulatory cell marker forkhead box P3 (FOXP3) (Table 1).
Association with OPV seroconversion and vaccine shedding
After FDR correction none of the 51 immune parameters showed a
significant individual association with OPV seroconversion or
shedding of vaccine virus as a marker of vaccine “take” (Table 1
and Supplementary Table 1). Measures of mucosal inflammation
(e.g., fecal calprotectin, myeloperoxidase) and systemic inflamma-
tion (e.g., plasma IFN-γ and IL-1β) measured in plasma at the time
of vaccination were not significantly different among infants
according to their subsequent seroconversion or vaccine shedding
status (Table 1 and Supplementary Fig. 1). The number of
regulatory CD4+ T cells homing to the small intestine (CCR9+)
was higher in infants who failed to seroconvert, but this was not
significant after FDR correction (16.4 vs. 13.5 cells/μl, FDR p-value
= 0.483).
Statistical learning analysis
We used supervised learning (random forest) analysis of immune
measurements taken at the time of vaccination to determine
whether they allowed accurate out-of-sample prediction of infant
response to OPV or receipt of azithromycin. We analyzed the
accuracy of each module independently and combined using 10-
fold cross-validation and plotted the correlation network for the
eight most important variables in a single run of the random forest
algorithm for the combined analyses (Fig. 3).
Combining all measurement modules for 126 infants with
complete data we were able to predict seroconversion with a
median accuracy across all cross-validation samples of 58%
(interquartile range (IQR): 50–69%; Fig. 3a). This compares with
50% accuracy expected by random choice assuming a priori equal
probabilities of seroconversion or not. The most important
measurement modules contributing to this modest predictive
accuracy were enteric pathogens (enterovirus in stool), ex vivo
flow cytometry measurements (regulatory CD4+ T cells expressing
CCR9), neutrophil and the (correlated) total leukocyte count and
plasma cytokines (Fig. 3c). The out-of-sample predictive accuracy
for the combined modules to predict shedding of poliovirus after
immunization was not different to that expected by chance
(Supplementary Fig. 2).
Infant study arm (receipt of azithromycin or placebo 2 weeks
before sample collection at vaccination) was predicted with a
median accuracy of 66.7% (IQR: 58.3–75.0%; Fig. 3b). All
measurement modules contributed to this predictive accuracy
with the exception of demography (as expected because of the
randomized study design). Important variables included measures
of intestinal inflammation and integrity (calprotectin, myeloper-
oxidase, α1-antitrypsin), regulatory T cells homing to the intestine
and enteric bacterial pathogens (Campylobacter, enteroaggrega-
tive Escherichia coli) (Fig. 3d).
DISCUSSION
Our study provides insight into the ecology of the gastrointestinal
tract and the developing immune system in infants in a low-income
setting with a high load of bacterial and viral intestinal pathogens.
Perturbing the intestinal microbiota with azithromycin allowed us
to overcome some of the difficulties with complex association data
in observational studies and reveals distinct bacteria-associated
changes in infant immune status. To analyze these complex data
-1.0
0.0
1.0
EE
biomarkers
plasma
cytokines
and CRP
leukocyte
counts
ex vivo
FACS
a b
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IL8
MIG
MCP1
HGF
IL15
IL2
IL1b
IFNa
CD4+b7+
CD4+FOXP3+b7+
sCD14
IP10
MIP1b
EGF
a1 anti-trypsin
calprotectin
MPO
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Fig. 2 Correlation and clustering analysis of infant immune status variables. a Pearson’s correlation coefficient for the 51 variables in each
of the 4 measurement “modules”. Pairwise comparisons are based on all available data (n= 292 infants for data on biomarkers of
environmental enteropathy (EE), plasma cytokines and CRP, and leukocyte counts; and n= 129 infants for data on ex vivo flow cytometry). b
Heatmap for each infant with variables (rows) clustered using Ward’s minimum variance hierarchical clustering method and infants (columns)
grouped by treatment arm and OPV seroconversion status. A tree with 6 clusters showing the grouping of the variables is shown on the left of
the heatmap and the variables included in each group on the right. In both plots the variables were log-transformed, normalized, and
truncated at +/−3 standard deviations before analysis and plotting. Color bars indicate the scale for each plot. Only infants with complete
data for all variables were included and invariant variables after normalisation and truncation were removed (126 infants, 37 variables). SN
seroconversion negative, SP seroconversion positive, Az azithromycin arm, Pl placebo arm.
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including over 30 infection and 50 immune parameters per child
we used a systems biology approach to identify immune signatures
that could predict OPV immunogenicity.
We did not find a distinct immune phenotype that was strongly
associated with OPV seroconversion or shedding among the
immune parameters that we measured. As previously reported,
infection with enteroviruses at the time of vaccination was more
common among infants who failed to seroconvert to OPV31, but
these infections were not associated with a distinct immune
signature in peripheral blood or stool (Fig. 2b). Combining all
measurements in a machine-learning (random forests) analysis, OPV
seroconversion could be predicted with an out-of-sample accuracy
of 58% (IQR: 50–69%), only a modest improvement over the 50%
accuracy expected by chance. Apart from enterovirus infection, the
variables with the highest importance in this analysis were the
numbers of CD4+ T cells homing to the small intestine (CCR9+),
particularly CD4+FOXP3+ (regulatory) T cells, and also circulating
leukocytes, in particular neutrophils, and the fecal biomarker of
enteropathy α1-antitrypsin. This is potentially suggestive of a local
intestinal inflammation that inhibits OPV immunogenicity. CD4+
regulatory T cells have a well-established role in intestinal
inflammation—they home towards the inflamed gut and can
resolve intestinal inflammation32. They are also involved in the early
antiviral immune response to mucosal infection in mice33,34.
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Fig. 3 Random forests analysis to predict seroconversion and study arm. The accuracy of random forests analysis to predict a
seroconversion and b study arm for each measurement module individually and all modules combined. For each analysis we performed a 10-
fold cross-validation repeated 20 times. The boxes correspond to the interquartile range for the accuracies in the prediction set, with the solid
line showing the median and the whiskers extending to the 10th and 90th percentile. The dashed line indicates expected accuracy if a
random choice were made. The top eight most important variables that predict c seroconversion and d study arm in one best fit full random
forests model are shown as correlation networks. The color of the circle around each variable indicate whether they were positively (green) or
negatively (red) associated with seroconversion or azithromycin respectively. The size of each network node indicates the strength of
correlation with the outcome and the color indicates whether the variable describes pathogens in stool (orange), EE biomarkers (blue) ex vivo
T-cell and total leukocyte count data (pink), or plasma cytokines (green) (as for a and b). Demographic variables were not among the top eight
variables. Lines connect circles with a Spearman correlation coefficient of at least 0.2, with the color of the line indicating the strength of the
correlation (indicated by color scale bar). EV enterovirus, EGF epidermal growth factor, IL2R interleukin-2 receptor, TLC total leukocyte count,
NC neutrophil count, MPO fecal myeloperoxidase, EAEC enteroaggregative Escherichia coli. Analysis is for infants with complete data for all
variables only (n= 126 infants).
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However, without mucosal tissue samples, it is difficult to conclude
their role in the response to OPV in these infants.
Shedding of poliovirus after vaccination was strongly correlated
with seroconversion, and markers of inflammation were some-
what raised among infants who did not shed poliovirus after
vaccination as seen for seroconversion (although these differences
were not significant in univariate analyses after FDR correction).
However, shedding of OPV after immunization was not predicted
with any degree of accuracy above that expected by chance on
the basis of the immune parameters that we measured.
We did find significant seasonal variation in several immune
parameters, including raised measures of intestinal inflammation
and lower levels of systemic proinflammatory plasma cytokines
(IL-1β, IFN-γ) and neutrophil counts in the warmer months of
September to October compared with November to December.
This may reflect differences in exposure to infection, with many
diarrheal pathogens more common in the warmer months in this
population and respiratory illness peaking in colder months9,35.
Treatment of infants with azithromycin resulted in a network of
correlated immune changes that were distinct from those
associated with OPV seroconversion. This is consistent with the
absence of an effect of treatment on vaccine response. Prior
receipt of azithromycin or placebo could be predicted with a
median of 67% out-of-sample accuracy (IQR 58–75%). In addition
to the previously reported reduction in bacterial pathogens and
biomarkers of intestinal inflammation, important variables in the
random forests analysis included gut-homing (β7+ or CCR9+)
regulatory CD4+ T cells and neutrophil counts. Systemic
inflammation measured by CRP in plasma was not affected by
treatment, despite the known anti-inflammatory effects of
azithromycin, which may be mediated both through a reduction
in bacterial load and direct effects on cell signaling pathways36.
Our study has a number of limitations. It is observational in
nature and lacks mucosal tissue that would have allowed a more
direct assessment of intestinal immunity. Although pediatric
endoscopy has an excellent safety record, we decided not to
take intestinal biopsies because infants were asymptomatic and
healthy despite raised levels of EE biomarkers. We therefore relied
on inference from the systemic compartment and from circulating
cells expressing mucosal and gut-homing receptors/integrins.
Further investigation of underlying mechanisms responsible for
oral vaccine failure may benefit from examination of tissue
biopsies taken during diagnostic procedures and use of appro-
priate in vitro and animal models37,38.
An additional limitation is that we focused on a single
population of seronegative infants in south India with high levels
of EE biomarkers. Indeed, fecal biomarkers of inflammation in our
study are among the highest reported from any cohort described
so far in the world39. It will be important to determine how our
findings in this population translate to other settings, such as in
sub-Saharan Africa, where oral vaccine immunogenicity is also
compromised. We deliberately enrolled infants without detectable
serum neutralizing antibodies to serotype 3 poliovirus, but these
infants were previously exposed to trivalent oral poliovirus vaccine
and may have developed an immune response that was not
detectable in blood or that had waned by the time of enrollment.
It is therefore possible that our population included both naïve
and immunologically primed infants with a potential impact on
the subsequent immunogenicity of OPV. However, we were not
able to distinguish such a population and analysis of infant
vaccination history and seroprevalence at screening for eligibility
was consistent with a simple hypothesis of a small, independent
probability of vaccine failure per dose of earlier vaccine40.
Finally, we do not report on the commensal intestinal microbiota
here, which is known to have immunomodulatory effects3.
However, in a subset of infants from this study the bacterial
microbiota was assessed by 16S rRNA sequencing of stool and
found not to correlate with OPV immunogenicity or shedding28.
In conclusion, our study did not find a strong predictor of OPV
immunogenicity in this population in south India. Infection with
enteric viruses and changes in gut-homing regulatory T cells
showed a modest association with OPV immunogenicity. Further
work would be required to investigate this possible association,
ideally including mucosal samples. It is clear that intestinal
homeostasis among these infants is skewed towards an inflam-
matory state that maintains health in the presence of multiple
intestinal pathogens. On average, each infant had >2 pathogen
targets detected in stool using TAC but only 2% had diarrhea at
enrollment31. We do not fully understand the mechanisms
responsible for the development and maintenance of this
inflammatory environment, although they are likely to reflect
the integration by the infant immune system of multiple signals
from intestinal viral and bacterial pathogens and commensals3,41.
Further investigation of these mechanisms in humans and in
animal models may identify pathways that could be targeted by
coadministered drugs or adjuvants that enhance the immune
response to oral vaccines.
Translating our current findings to interventions to improve oral
vaccine immunogenicity and effectiveness is difficult. Treatment
of enteric virus infection or directly perturbing infant intestinal
immune environment from an inflammatory state that might be
adaptive in this community may well be detrimental. However,
alternative approaches could include changes to an earlier
immunization schedule, including neonatal dosing, before expo-
sure to pathogenic enteric viruses, or interventions to promote
gut health of neonates, such as maternal immunization, water and
sanitation interventions or promotion of exclusive breastfeeding.
METHODS
Study population
Infants aged 6–11 months living in Vellore, south India, were enrolled in a
double-blind, randomized, placebo-controlled trial to study the effect of a
3-day course of azithromycin on serotype-3 poliovirus vaccine immune
response. Infants were enrolled in the study if they lacked detectable
antibodies against serotype 3 poliovirus at a dilution of 1 in 8 and were
medically fit. They were excluded if they had a history of allergic reaction
after oral poliovirus vaccine, had chronic diarrhea (>14 days), were
receiving immunosuppressant medication, or they or their mother had
syndromic or documented evidence of being immunocompromised. Full
details of the study population and the result of treatment with
azithromycin have been published previously31. For the present study,
we selected a random sample of 300 infants from those who had
completed the trial and had sufficient sample volumes, with equal
numbers chosen by study arm and poliovirus seroconversion status
(defined as the detection of serotype-3 poliovirus-specific serum
neutralizing antibodies at a dilution of 1 in 8 or higher in blood taken
21 days after vaccination).
The trial was performed in accordance with good clinical practice and
ethical principles of the Declaration of Helsinki, including the collection of
written informed consent from parents. The study was approved by the
Institutional Review Board of the Christian Medical College Vellore and the
Drugs Controller General of India. All biological samples were coded with a
unique ID linked to the study participant ID, to ensure that only
anonymized samples were analyzed and that laboratory personnel were
blinded to study group assignment. The trial was registered with the
Clinical Trials Registry India on 9 May 2014, number CTRI/2014/05/004588.
Full blood count and isolation of peripheral blood mononuclear
cells
Total white blood cell count and differential leukocyte count (lymphocytes,
neutrophils, monocytes and eosinophils) were performed in blood collected
in EDTA tubes based on standardized methods by Leishman’s staining in a
Neubauer’s chamber by trained technicians using standardized methods.
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll Hypaque
gradient method on the day of vaccination (day 14 of the trial). PBMC were
analyzed ex vivo using flow cytometry (FACS), within 4–6 h of collection.
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FACS analysis
Samples were acquired on a BD FACSAria™ III running a BD FACSDIVA
Ver.8.0.1 software and results analyzed using FlowJo X 10.0.6 software
(Supplementary Table 2). Cell viability was determined using LIVE/DEAD®
Fixable Aqua Dead Cell Stain Kit. Appropriate single stained controls and
florescent minus one (FMO) controls were used. The PBMCs collected on
the day of administration of monovalent OPV3 (pre-vaccination), were
assessed for the lymphocyte subsets with a special focus on the gut-
homing subpopulations. Staining was performed for CD3, CD4, CCR6,
CCR9, FOXP3, and β7-integrin (Supplementary Table 2). This allowed us to
define the following populations: CD3+ T cells, CD3+CD4+ T cells,
CD3+CD4+FOXP3+ regulatory T cells, and investigate CCR6+, CCR9+,
and integrin β7+ gut homing subsets (gating strategy shown in
Supplementary Fig. 3).
Plasma cytokine and C-reactive protein levels
Plasma was separated from blood samples collected on the day of
vaccination and stored at −80 °C until analysis. Samples were tested for a
diverse range of pro-inflammatory and anti-inflammatory cytokines,
growth markers and chemokines using the Human Cytokine Magnetic
30-plex panel and analyzed using a LuminexTM platform. This includes
chemokines (Eotaxin, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, and RANTES),
growth factors (EGF, FGF-basic, HGF, and VEGF), and cytokines (G-CSF, GM-
CSF, IFN-α, IFN-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12
(p40/p70), IL-13, IL-15, IL-17, and TNF-α). Results were calculated using the
5PL fit equation on the Bio-plex Manager software Version 6.1. Plasma C-
reactive protein (CRP) levels were estimated using the ProcartaPlex Human
CRP Simplex kit and analyzed using the LuminexTM platform.
Plasma cytokine and CRP assays were run across multiple 96-well plates.
We found significant plate-to-plate variation in estimated analyte levels
using the LuminexTM platform. This variation remained even after using
more stringent thresholds for analyte minima (at value of 6th dilution
standard across 7 dilutions) and checking readings across plates used to fit
the standard curve were within 10% of each other. For example, the F-
statistic for IL12 across the five plates used for plasma cytokine
measurement was 22.2 (p-value < 0.001) and for CRP across the four
plates used was 16.5 (p < 0.001). The distribution of samples across plates
was approximately equal (plasma cytokines) or deliberately randomized
(CRP) with respect to study arm (azithromycin vs. placebo) and outcome
(seroconversion) and we therefore included these measurements in our
analyses. However, this highlights the importance of checking batch
effects in high-throughput studies.
Environmental enteropathy biomarkers
Stool biomarkers of inflammation (myeloperoxidase, calprotectin), protein-
losing enteropathy (α1-antitrypsin) and immune activation (neopterin),
and plasma biomarkers of microbial translocation (soluble CD14 and
endotoxin-core IgG) and epithelial damage (intestinal fatty acid binding
protein) were measured on the day of vaccination using commercial
enzyme-linked immunosorbent assays (ELISA)31. Stool aliquots for the fecal
biomarker ELISA assays were supplemented with a cocktail of protease
inhibitors before being stored at −70 °C.
Detection of poliovirus shedding and stool pathogens
Shedding of serotype 3 Sabin poliovirus in stool samples collected 7 days
after vaccination was assessed using a singleplex quantitative real-time
PCR, using RNA extracted by Vx reagents on a Qiaxtractor42. Bacterial, viral,
and eukaryotic pathogens were analyzed using total nucleic acid extracted
from stool samples collected on the day of vaccination using an
enteropathogen Taqman Array Card (TAC) quantitative PCR assay
developed by the Division of Infectious Diseases and International Health,
University of Virginia31,43. TAC assay targets allowed identification of
pathogenic bacteria (Aeromonas, Campylobacter, Clostridium difficile,
Helicobacter pylori, Salmonella, Shigella, Vibrio cholerae, and enteroaggre-
gative, enteropathogenic, enterotoxigenic and shiga-toxin producing
Escherischia coli (EAEC, EPEC, ETEC, and STEC)), viruses (Adenovirus,
Astrovirus, Enterovirus, Norovirus, Rotavirus, and Sapovirus) and eukaryotes
(Ancylostoma, Ascaris, Cryptosporidium, Cyclospora, Enterocytozoon bieneusi,
Entamoeba histolytica, Encephalitozoon intestinalis, Giardia, Isospora,
Necator, Strongyloides, Trichuris).
Statistical analysis
Data on fecal and plasma biomarkers of environmental enteropathy,
circulating ex vivo T-cell phenotype, plasma cytokines and leukocyte
counts for samples collected on the day of vaccination (study day 14) were
compiled in a single dataset. Correlation among the variables was assessed
by calculating Pearson’s correlation coefficient for the log-transformed
variables rescaled to have a mean of zero and standard deviation (SD)= 1.
Univariable comparisons between groups were based on analysis of
variance for the log-transformed variables or Wilcoxon’s (non-parametric)
rank sum test for the untransformed data (two-sided tests). p-values for the
univariable tests of significance were corrected for multiple comparisons
using FDR correction44.
Hierarchical cluster analysis of variables in the complete dataset was
performed using Ward’s minimum variance criterion45. Heatmaps of the
clustered dataset were plotted to visualize the relationship between infant
immune phenotype and study arm/seroconversion status. The association
between the immune phenotype data and classification of infants
according to their seroconversion status or study arm was assessed using
the random forests algorithm46. For each analysis we report the median
accuracy from a 10-fold cross-validation using 20 random forests for each
fold. Variables were ranked by their importance in the random forests
analysis and the top eight most important variables plotted in a correlation
network with links between pairs of variables shown if their Spearman rank
correlation coefficient was greater than 0.2. Variable importance was
assessed by the mean decrease in the Gini coefficient resulting from their
inclusion in the random forest model.
All analyses were performed in the R programming language (R Core
Team. R: A Language and Environment for Statistical Computing. www.R-
project.org). Individual R packages were used during the analysis including
pheatmap for the heatmap plots, beeswarm for the univariable plots,
randomForest for the random forest analyses, and igraph for the
network plots.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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